Ligand Pharma (LGND) Exec Sells $1.52 Million in Stock
Published on Β· Source: investing.com
AI Summary
Summarized by AI from the source belowAndrew Reardon, Chief Legal Officer of Ligand Pharmaceuticals (LGND), sold company stock valued at $1.52 million. The transaction involved the sale of 14,950 shares at an average price of $101.61 each. This sale follows other insider transactions within the company over recent months. Insider sales can sometimes indicate an executive's view on the stock's current valuation or future prospects. This matters to investors as such transactions might influence perceptions regarding the company's future performance and stock value.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Key numbers
- Stock sale value
- $1.52 million
What could hurt
- Insider sales might signal concerns about the company's future valuation.
The background
Insider trading refers to company executives trading their own company's stock, seen as a potential signal of confidence or concern.
Questions readers ask
How much Ligand Pharma stock did Andrew Reardon sell?
Andrew Reardon sold $1.52 million worth of Ligand Pharmaceuticals stock.
What does insider stock selling indicate?
Insider selling can suggest an executive's view on current stock value, but it's not a definitive indicator of future performance.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
